Gynecologic cancer in HIV-infected women: treatment and outcomes in a multi-institutional cohort

Objective: To evaluate gynecologic cancer treatments in HIV-infected women for adherence to National Comprehensive Cancer Network (NCCN) guidelines and to describe survival by adherence to guidelines. Design: Beyond cervical cancer, there are little data on treatment and outcomes for these women. This is a retrospective cohort study of HIV-infected women with gynecologic cancers. Methods: HIV-infected women with gynecologic cancers from 2000 to 2015 were identified at two urban, comprehensive cancer centers. Chart reviews extracted demographic, HIV, and cancer-related variables. Cancer treatment was evaluated for adherence to NCCN guidelines. Overall survival was compared between those who received NCCN adherent and nonadherent cancer care. Results: Fifty-seven women were identified; 15 vulvar (26%), 26 cervical (46%), nine ovarian (16%), and seven endometrial (12%) cancers. Median time from HIV to cancer diagnosis was 8.5 years, and 88% of women were black. Thirty patients (53%) had stage I, and 27 (47%) had stage II–IV disease. Overall, 28 women (49%) received NCCN-adherent care; 22 of 30 stage I (73%) and six of 27 stage II–IV patients (22%). Among 29 women not receiving NCCN-adherent care, 69% were due to patient-related factors or toxicity. Among women with II–IV cancers, 48-month survival was higher in women who received NCCN-adherent care than those who did not (60 versus 28%). Conclusion: Most HIV-infected women with advanced gynecologic cancers did not receive NCCN-adherent care and had worse survival compared to those who did. Focus on treatment-related toxicities and patient-related barriers to cancer care are necessary in this population.

[1]  G. Suneja,et al.  Cancer care disparities in people with HIV in the United States , 2017, Current opinion in HIV and AIDS.

[2]  A. Jemal,et al.  Disparities in cancer treatment among patients infected with the human immunodeficiency virus , 2016, Cancer.

[3]  Judith A. Long,et al.  Cancer Treatment in Patients With HIV Infection and Non-AIDS-Defining Cancers: A Survey of US Oncologists. , 2015, Journal of oncology practice.

[4]  G. Copeland,et al.  Cancer treatment disparities in HIV-infected individuals in the United States. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  H. Torres,et al.  Management of HIV infection in patients with cancer receiving chemotherapy. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  S. Lewin,et al.  The end of AIDS: HIV infection as a chronic disease , 2013, The Lancet.

[7]  T. Jobo,et al.  Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. , 2013, The Lancet. Oncology.

[8]  Melanie A. Williams,et al.  Disparities in the treatment and outcomes of lung cancer among HIV-infected individuals , 2013, AIDS.

[9]  Melanie A. Williams,et al.  Disparities in the treatment and outcomes of lung cancer among HIV-infected people in Texas. , 2012 .

[10]  J. Goedert,et al.  Cancer burden in the HIV-infected population in the United States. , 2011, Journal of the National Cancer Institute.

[11]  P. Sullivan,et al.  Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. , 2008, Annals of internal medicine.

[12]  H. Napo,et al.  HIV-related cancer of the vulva in young women: A clinicopathologic study of five cases , 2008, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.

[13]  J. Goedert,et al.  Risk of breast, ovary, and uterine corpus cancers among 85 268 women with AIDS , 2006, British Journal of Cancer.

[14]  Lalit Kumar,et al.  Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer , 2006, Indian Journal of Medical and Paediatric Oncology.

[15]  W. Winter,et al.  Vulvar Cancer in Human Immunodeficiency Virus-Seropositive Premenopausal Women: A Case Series and Review of the Literature , 2005, Journal of lower genital tract disease.

[16]  Neeta Kumar,et al.  Unsuspected peritoneal leishmaniasis in an HIV-positive woman with ovarian cancer. , 2004, Acta cytologica.

[17]  M. Moodley,et al.  Human immunodeficiency virus (HIV) infection and ovarian granulosa cell tumour in association with endocrine manifestations , 2004, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.

[18]  M. Moodley,et al.  Ovarian germ cell malignancy and human immunodeficiency virus (HIV) infection: a case report. , 2003, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[19]  J. Goedert,et al.  Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. , 2000, Journal of the National Cancer Institute.

[20]  N. Rosenshein,et al.  The use of paclitaxel and cisplatin in a patient with epithelial ovarian cancer and human immunodeficiency virus. , 2000, Gynecologic oncology.

[21]  M. Quinn,et al.  First reported case of endometrial carcinoma in association with HIV infection. , 1999, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[22]  D. Fishman,et al.  Effect of combination chemotherapy with cisplatin and cyclophosphamide on human immunodeficiency virus type-1 surrogate markers in a patient with advanced epithelial ovarian cancer. , 1995, Gynecologic oncology.

[23]  P. Rose,et al.  Advanced ovarian carcinoma managed in an HIV-positive patient. , 1993, Gynecologic oncology.